Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension... Show more
Tenax Therapeutics is a Phase 3, development-stage biopharmaceutical company headquartered in Chapel Hill, North Carolina, focused on novel therapies for cardiovascular and pulmonary diseases with high unmet medical need. Its prioritized product candidate is TNX-103, an oral formulation of levosimendan, a first-in-class K-ATP channel activator and calcium sensitizer being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition with no approved therapy in the United States.
Levosimendan is already approved for intravenous use in acutely decompensated heart failure in roughly 60 countries, though it is not available in the U.S. or Canada. The company has also deprioritized its imatinib program (TNX-201) for pulmonary arterial hypertension. As a development-stage company with no marketed products or product revenue, Tenax's valuation is driven almost entirely by clinical trial outcomes and regulatory milestones, making the stock highly sensitive to binary data readouts.
Over the trailing 30-day period, TENX declined approximately 27%, moving from a $1.72 close on October 23, 2026, to a $1.25 close on November 20, 2026. The downtrend was persistent rather than driven by a single session, with the stock grinding lower through mid-November as sentiment remained cautious.
The broader three-month picture is similarly negative. From a late-August close near $1.75, the stock fell roughly 29% through late November, despite a brief recovery above $2.30 in late August. That intra-quarter volatility reflects an attempt by investors to weigh the company's enriched-population strategy against the backdrop of the earlier pivotal trial miss and ongoing legal and analyst scrutiny.
Several verified developments shaped the stock's decline during the 30-day window. On November 5, 2026, Tenax reported third-quarter financial results, posting a net loss of $16.7 million (a loss of $0.31 per share) and disclosing cash of $113.7 million. Management guided that the cash position is expected to fund operations through fiscal 2028, though the plan is subject to change pending the outcome of an FDA Type C meeting.
At the same time, the company confirmed it had temporarily paused enrollment in LEVEL-2, its second global Phase 3 trial, to amend the protocol and enrich the study population for patients with a baseline six-minute walk distance (6MWD) of 100 to 300 meters, or 301 to 400 meters with elevated right atrial volume index. While framed as a data-driven refinement, the pause added uncertainty around trial timelines.
Sentiment was further pressured by analyst downgrades. Guggenheim moved the stock to Neutral, and Chardan downgraded it to Neutral with a reduced price target, citing the LEVEL readout. In addition, several securities class action lawsuits were announced in November 2026 alleging misrepresentations tied to the LEVEL trial, with a lead plaintiff deadline of December 28, 2026. The combination of clinical uncertainty, litigation risk, and reduced analyst conviction contributed to the steady slide.
The dominant driver of the quarterly trend was the August 10, 2026 topline readout from the Phase 3 LEVEL trial. Tenax disclosed that TNX-103 did not meet its primary endpoint of improvement in 6MWD versus placebo, nor its key secondary endpoint on the Kansas City Cardiomyopathy Questionnaire total symptom score. Shares fell roughly 90% in a single session to close near $1.38.
Since then, the company has emphasized prespecified and exploratory subgroup analyses showing greater benefits in more symptomatic patients, including a 26.3-meter improvement in 6MWD among patients below the trial's median baseline walk distance and marked reductions in NT-proBNP. However, the market has remained skeptical of a subgroup-based path to approval, and the subsequent litigation announcements, downgrades, and the temporary LEVEL-2 enrollment pause have kept the stock under pressure throughout the quarter.
Tickeron's Trending AI Robots page highlights a curated selection of the platform's AI-driven trading bots. While Tickeron offers hundreds of automated trading systems covering thousands of tickers, only the top-performing and most relevant bots are featured in this section, giving users a streamlined view of current market opportunities. The bots vary in trading strategy, timeframe, and performance metrics, allowing investors to compare approaches that range from short-term momentum to longer-horizon positioning. For those seeking a data-driven complement to their own research, exploring the Trending AI Robots section can be a useful starting point.
Looking ahead, the most consequential catalyst is the outcome of the FDA Type C meeting on the development path for levosimendan in PH-HFpEF. Investors should also monitor the LEVEL-2 protocol amendment and the timing of enrollment resumption, as well as the LEVEL-2 design paper and further development updates expected in the first quarter of 2027. Legal developments, including the December 28, 2026 lead plaintiff deadline in the securities class actions, could also influence sentiment. Finally, the company's cash runway and any changes to its operating plan following regulatory discussions will be key factors in assessing its ability to execute the amended clinical program.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 73 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for TENX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 27 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.596). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel therapeutic products
Industry Biotechnology